Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

Xavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL.

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The companies are allegedly selling "research grade" GLP-1 weight loss drugs that are not FDA-approved, and are selling the products without a pharmacy license.

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday. (Scripps News) ...

Since being approved by the FDA in 2021, the drugs have become so popular that, at one point, supply couldn't keep up with the demand.